Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

HCV lookback proposed rule

This article was originally published in The Gray Sheet

Executive Summary

FDA's Center for Biologics Evaluation & Research intends to issue a proposed rule making the hepatitis C virus lookback program a requirement for blood establishments and health care providers, instead of relying on voluntary compliance with a Sept. 23 revised guidance ("The Gray Sheet, Sept. 28, p. 13). The lookback covers patients who may have received HCV-contaminated blood or blood products between 1988 and 1992. The rule is not anticipated to differ substantively from the guidance, which says blood establishments must begin to notify blood "consignees" (hospitals, transfusion services, physicians, etc.) about contaminated blood or blood products by March 23, 1999, and finish by March 23, 2000. Transfusion services must then notify recipients by March 23, 2001

You may also be interested in...



‘Highly Questionable’ GMP Compliance In Pakistan Prompts New Licensing System

Increased fines and penalties are on the cards for manufacturing facilities that fail to comply with proposed new requirements.

Infographic: 20 Years Of Mega-Deals

The biopharma sector is often accused of a being a slow-moving engine, but a look back over the last 20 years reveals that a lot has changed. In Vivo explores the history of high-impact M&A transactions in the industry between 1999 and 2019. 

Belgians To Tackle High Benzodiazepine Use

The Belgian authorities are taking steps to reduce the consumption of benzodiazepine-containing medicines, and have also reiterated the risks associated with the increasing use of opioid medications. 

UsernamePublicRestriction

Register

MT011096

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel